What is HC Wainwright’s Forecast for TBPH FY2028 Earnings?

Theravance Biopharma, Inc. (NASDAQ:TBPH) – Equities researchers at HC Wainwright issued their FY2028 earnings per share estimates for Theravance Biopharma in a report released on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will earn $1.11 per share for the year. HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Theravance Biopharma’s current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Theravance Biopharma’s FY2029 earnings at $3.87 EPS.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The business had revenue of $18.75 million during the quarter, compared to analyst estimates of $29.90 million.

Theravance Biopharma Price Performance

Shares of Theravance Biopharma stock opened at $9.27 on Wednesday. The firm has a fifty day moving average price of $9.34 and a two-hundred day moving average price of $8.92. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90. The company has a market cap of $455.84 million, a PE ratio of -9.18 and a beta of 0.21.

Insider Activity at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now directly owns 309,565 shares in the company, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of TBPH. Newtyn Management LLC grew its holdings in shares of Theravance Biopharma by 5.7% during the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company’s stock worth $44,767,000 after purchasing an additional 258,337 shares during the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Theravance Biopharma by 88.9% in the third quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock worth $2,462,000 after acquiring an additional 143,781 shares in the last quarter. Algert Global LLC acquired a new stake in shares of Theravance Biopharma during the third quarter worth $851,000. Dimensional Fund Advisors LP lifted its stake in Theravance Biopharma by 20.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company’s stock valued at $5,211,000 after acquiring an additional 95,304 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Theravance Biopharma by 71.1% in the 4th quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company’s stock valued at $1,815,000 after acquiring an additional 80,140 shares in the last quarter. 99.10% of the stock is currently owned by institutional investors and hedge funds.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.